Product
Poly ICLC
Aliases
Hiltonol, poly-ICLC, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Poly I:Poly C with Poly-L-Lysine Stabilizer (3 other aliases)
17 clinical trials
56 indications
Indication
Breast Cancer, Stage IVIndication
Stage IV Cutaneous MelanomaIndication
Cutaneous MelanomaIndication
MelanomaIndication
Conjunctival MelanomaIndication
Breast CarcinomaIndication
Metastatic Mucosal MelanomaIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
Stage IV Breast Cancer AJCC v8Indication
Recurrent Acral Lentiginous MelanomaIndication
Breast CancerIndication
Acral Lentiginous MelanomaIndication
Unresectable Mucosal MelanomaIndication
Diffuse Hemispheric GliomaIndication
H3 G34 mutationIndication
Metastatic MelanomaIndication
melanomaIndication
Cutaneous Squamous Cell CarcinomaIndication
Merkel Cell CarcinomaIndication
Soft Tissue SarcomaIndication
Bone SarcomaIndication
Non-Hodgkin lymphomaIndication
Head and Neck Squamous Cell CarcinomaIndication
Triple-Negative Breast CarcinomaIndication
GlioblastomaIndication
Stage IV Non-Small Cell Lung CancerIndication
Squamous Cell CarcinomaIndication
Lung CancerIndication
Cervical CancerIndication
Bladder CancerIndication
Ovarian CancerIndication
Hepatocellular CarcinomaIndication
Small Cell Lung CancerIndication
Microsatellite Instability HighIndication
Stomach CancerIndication
Esophageal cancerIndication
Platinum-Resistant Ovarian CarcinomaIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Follicular LymphomaIndication
NOSIndication
Brain TumorsIndication
fallopian tube carcinomaIndication
Primary Peritoneal CarcinomaIndication
MyelofibrosisIndication
Essential ThrombocythemiaIndication
Myeloproliferative NeoplasmIndication
Neurofibromatosis type 1Indication
Low-grade gliomaIndication
Pancreatic CancerClinical trial
PNV21-001: A Phase I Study of a Personalized Multi-Peptide Neo-Antigen Vaccine in Breast Cancer and PD1/PD-L1 Inhibitor-Refractory MelanomaStatus: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Pilot Study to Evaluate the Safety and Feasibility of Neoantigen-Targeted Dendritic Cell Vaccination in Diffuse Hemispheric Glioma, H3 G34-MutantStatus: Not yet recruiting, Estimated PCD: 2027-03-08
Clinical trial
A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable DiseaseStatus: Recruiting, Estimated PCD: 2025-01-09
Clinical trial
In Situ Vaccination With Flt3L, Radiation, and Poly-ICLC Combined With Pembrolizumab in Patients With Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, and Head and Neck Squamous Cell CarcinomaStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase I Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Antibody Pembrolizumab With Autologous Tumor Lysate-Pulsed Dendritic Cell Vaccination in Patients With Surgically Accessible Recurrent/Progressive GlioblastomaStatus: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLCStatus: Not yet recruiting, Estimated PCD: 2026-06-22
Clinical trial
Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-02-01
Clinical trial
A Randomized Phase 2 Trial of Atezolizumab (MPDL3280A), SGI-110 and CDX-1401 Vaccine in Recurrent Ovarian CancerStatus: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
Pilot Study of a Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular LymphomaStatus: Terminated, Estimated PCD: 2020-09-24
Clinical trial
Pilot Study of Atezolizumab Plus PGV001, a Multipeptide Personalized Neoantigen Vaccine, in Patients With Locally Advanced or Metad or Metastatic Urothelial CancerStatus: Completed, Estimated PCD: 2021-10-12
Clinical trial
A Placebo-Controlled, Single (Participant) Blind Trial to Evaluate the Safety, Tolerability, and Early Immunogenicity of Peptide-Pulsed Dendritic Cell Vaccination With Nivolumab and Ipilimumab in Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-MutantStatus: Not yet recruiting, Estimated PCD: 2029-12-01
Clinical trial
A Phase II Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade GliomasStatus: Completed, Estimated PCD: 2019-07-01
Clinical trial
A Phase I Open Label Peptide Based Vaccine in Patients With Myeloproliferative Neoplasm Harboring CALR MutationsStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase I/IIb Study of DEC205mAb-NY-ESO-1 Fusion Protein (CDX-1401) Given With Adjuvant Poly-ICLC in Combination With INCB024360 for Patients in Remission With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 AntigenStatus: Completed, Estimated PCD: 2020-08-20
Clinical trial
A Phase II Trial of Poly-ICLC for Progressive, Previously Treated Low-Grade Gliomas in Children and Young Adults With Neurofibromatosis Type 1Status: Recruiting, Estimated PCD: 2026-02-15
Clinical trial
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of a Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant ChemotherapyStatus: Terminated, Estimated PCD: 2022-07-21